Filing Analysis
NVE Corp has executed a Sixth Amendment to its lease agreement for its office and manufacturing facility. The amendment extends the lease term through May 31, 2031.
📋 Key Facts
- Effective date of amendment: November 4, 2024.
- Lease extension: Adds 62 months to the term, extending expiration from March 31, 2026, to May 31, 2031.
- Rent increase: Monthly base rent increases from $15,416.24 (March 2026) to $17,214.21 starting April 1, 2026.
- Incentives: Includes two months of free base rent and a $100,000 improvement allowance subject to conditions.
- Facility details: Approximately 21,362 square feet used for offices, laboratories, and production.
NVE Corporation filed an 8-K to report quarterly results for the period ending September 30, 2024 and announced a quarterly cash dividend.
📋 Key Facts
- Quarterly earnings results for the period ended September 30, 2024 were furnished via press release (Exhibit 99).
- Board of Directors approved a quarterly cash dividend of $1.00 per share of common stock.
- Dividend record date is November 4, 2024.
- Dividend payment date is November 29, 2024.
NVE Corp held its 2024 Annual Meeting of Shareholders on August 1, 2024. The meeting resulted in the successful election of five incumbent directors and advisory approval for executive compensation and auditor selection.
📋 Key Facts
- Annual Meeting held on August 1, 2024.
- Five directors were elected: Terrence W. Glarner, Daniel A. Baker, Patricia M. Hollister, James W. Bracke, and Kelly Wei.
- Named executive officer compensation was approved via advisory vote (3,015,808 votes in favor).
- Boulay PLLP was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2025.
NVE Corporation filed an 8-K reporting its quarterly results for the period ended June 30, 2024 and announcing a quarterly cash dividend.
📋 Key Facts
- Quarterly earnings results for the period ending June 30, 2024 were furnished via press release (Exhibit 99).
- Board of Directors approved a quarterly cash dividend of $1.00 per share of common stock.
- Dividend record date is July 29, 2024.
- Dividend payment date is August 30, 2024.
NVE Corp announced the passing of Director Richard W. Kramp on May 2, 2024, and the subsequent election of Dr. Kelly Wei to fill his unexpired term on the Board of Directors.
📋 Key Facts
- Director Richard W. Kramp passed away on May 2, 2024.
- Dr. Kelly Wei was elected to the Board effective May 13, 2024.
- Dr. Wei will serve until the conclusion of the 2024 annual shareholders' meeting.
- Dr. Wei has been appointed to the Compensation Committee and Nominating and Corporate Governance Committee.
- The Board determined Dr. Wei is independent under NASDAQ Listing Rule 5605(a)(2).
NVE Corporation filed an 8-K reporting its financial results for the fiscal year and quarter ended March 31, 2024. Additionally, the Board approved a quarterly cash dividend of $1.00 per share.
📋 Key Facts
- Reporting period: Quarter and Fiscal Year ended March 31, 2024.
- Dividend declared: $1.00 per share of common stock.
- Record date for dividend: May 13, 2024.
- Payment date for dividend: May 31, 2024.
NVE Corporation filed an 8-K to report its quarterly results for the period ending December 31, 2023 and announced a quarterly cash dividend.
📋 Key Facts
- Quarterly earnings results for the period ended December 31, 2023 were furnished via press release (Exhibit 99).
- The Board of Directors approved a quarterly cash dividend of $1.00 per share of common stock.
- Dividend record date is January 29, 2024; payment date is February 28, 2024.
NVE Corp has entered into Amendment No. 10 to its Supplier Partnering Agreement with Abbott Laboratories (via Pacesetter, Inc.). The amendment extends the agreement term through December 31, 2024, and includes a pricing increase for the year 2024.
📋 Key Facts
- Amendment No. 10 to the Supplier Partnering Agreement was fully executed on January 2, 2024.
- The agreement term is extended through December 31, 2024.
- The amendment includes an increase in pricing for the year 2024.
- Counterparty is Abbott Laboratories (via subsidiary Pacesetter, Inc.).